ImmuONE

Executive Summary

ImmuONE is a United Kingdom-based private company at the forefront of in vitro respiratory immunology. Founded in 2013 and headquartered in London, the company specializes in developing immune-competent human airway models and alveolar macrophage assays for inhalation testing. Its core mission is to accelerate product safety assessments for drugs, biologics, and medical devices targeting respiratory diseases, thereby reducing reliance on animal models and enabling faster paths to market. By offering proprietary in vitro cell culture products and services, ImmuONE addresses critical needs in immunology and infectious disease research, providing clients with physiologically relevant platforms to evaluate immune responses and toxicity. Despite limited public financial data and a private status, ImmuONE occupies a niche yet expanding segment of the preclinical testing market. The increasing regulatory push for alternative methods to animal testing and the growing focus on respiratory health post-pandemic position the company for potential growth. Its platform could be instrumental in developing therapies for asthma, COPD, infections, and inhaled vaccines. While the company operates with a low profile, its technical capabilities suggest it could form strategic partnerships with pharmaceutical firms or contract research organizations. The overall conviction in ImmuONE’s commercial viability is moderated by the lack of disclosed revenue, partnerships, or clinical milestones, but its differentiated technology and market tailwinds support a cautious positive outlook.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of next-generation immune-competent airway model70% success
• Q4 2026Strategic partnership with a top-20 pharmaceutical company for inhalation toxicology services55% success
• TBDRegulatory acceptance of an in vitro assay as a replacement for animal testing in inhalation studies30% success